Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

94 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Modeling the novel SERD elacestrant in cultured fulvestrant-refractory HR-positive breast circulating tumor cells.
Dubash TD, Bardia A, Chirn B, Reeves BA, LiCausi JA, Burr R, Wittner BS, Rai S, Patel H, Bihani T, Arlt H, Bidard FC, Kaklamani VG, Aftimos P, Cortés J, Scartoni S, Fiascarelli A, Binaschi M, Habboubi N, Iafrate AJ, Toner M, Haber DA, Maheswaran S. Dubash TD, et al. Among authors: aftimos p. Breast Cancer Res Treat. 2023 Aug;201(1):43-56. doi: 10.1007/s10549-023-06998-w. Epub 2023 Jun 15. Breast Cancer Res Treat. 2023. PMID: 37318638 Free PMC article.
[Chemoradiotherapy in early stage Hodgkin's lymphoma].
Farha G, Nasr E, Ghosn M, Nasr DN, Nasr F, Kattan J, Azoury F, Aftimos P, Chahine G. Farha G, et al. Among authors: aftimos p. J Med Liban. 2011 Jul-Sep;59(3):122-5. J Med Liban. 2011. PMID: 22259898 French.
Successful treatment of Evans syndrome with Tacrolimus.
Tabchi S, Hanna C, Kourie HR, Aftimos P, El Osta L, Ghosn M. Tabchi S, et al. Among authors: aftimos p. Invest New Drugs. 2015 Feb;33(1):254-6. doi: 10.1007/s10637-014-0155-9. Epub 2014 Sep 12. Invest New Drugs. 2015. PMID: 25209619 No abstract available.
A phase II randomized study comparing navelbine and capecitabine (Navcap) followed either by Navcap or by weekly docetaxel in the first-line treatment of HER-2/neu negative metastatic breast cancer.
Ghosn M, Aftimos P, Farhat FS, Kattan JG, Hanna C, Haddad N, Nasr F, Chahine G. Ghosn M, et al. Among authors: aftimos p. Med Oncol. 2011 Dec;28 Suppl 1:S142-51. doi: 10.1007/s12032-010-9754-2. Epub 2010 Dec 7. Med Oncol. 2011. PMID: 21136213 Clinical Trial.
Effect of the COVID-19 pandemic on cancer treatment and research.
Saini KS, de Las Heras B, de Castro J, Venkitaraman R, Poelman M, Srinivasan G, Saini ML, Verma S, Leone M, Aftimos P, Curigliano G. Saini KS, et al. Among authors: aftimos p. Lancet Haematol. 2020 Jun;7(6):e432-e435. doi: 10.1016/S2352-3026(20)30123-X. Epub 2020 Apr 24. Lancet Haematol. 2020. PMID: 32339482 Free PMC article. No abstract available.
Phase 2 Study of Trabectedin in Patients With Hormone Receptor-Positive, HER-2-Negative, Advanced Breast Carcinoma According to Expression of Xeroderma Pigmentosum G Gene.
Awada A, Cortés J, Martín M, Aftimos P, Oliveira M, López-Tarruella S, Espie M, Lardelli P, Extremera S, Fernández-García EM, Delaloge S. Awada A, et al. Among authors: aftimos p. Clin Breast Cancer. 2016 Oct;16(5):364-371. doi: 10.1016/j.clbc.2016.05.005. Epub 2016 May 14. Clin Breast Cancer. 2016. PMID: 27266804 Clinical Trial.
94 results